Mersana Therapeutics, Inc. (NASDAQ:MRSN – Get Free Report) CFO Brian Deschuytner sold 8,089 shares of the company’s stock in a transaction on Wednesday, October 2nd. The shares were sold at an average price of $2.00, for a total transaction of $16,178.00. Following the sale, the chief financial officer now directly owns 100,422 shares in the company, valued at $200,844. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link.
Mersana Therapeutics Stock Performance
NASDAQ MRSN opened at $1.88 on Thursday. The company has a market cap of $230.04 million, a P/E ratio of -1.65 and a beta of 1.49. The company has a fifty day simple moving average of $1.68 and a 200 day simple moving average of $2.37. The company has a current ratio of 2.72, a quick ratio of 2.72 and a debt-to-equity ratio of 2.02. Mersana Therapeutics, Inc. has a 12-month low of $1.07 and a 12-month high of $6.28.
Mersana Therapeutics (NASDAQ:MRSN – Get Free Report) last issued its quarterly earnings data on Tuesday, August 13th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.03). Mersana Therapeutics had a negative net margin of 349.98% and a negative return on equity of 333.91%. The business had revenue of $2.30 million for the quarter, compared to analyst estimates of $8.72 million. During the same quarter in the prior year, the business earned ($0.47) earnings per share. The firm’s quarterly revenue was down 78.3% compared to the same quarter last year. Sell-side analysts predict that Mersana Therapeutics, Inc. will post -0.71 earnings per share for the current fiscal year.
Institutional Trading of Mersana Therapeutics
Wall Street Analyst Weigh In
MRSN has been the topic of several research analyst reports. Robert W. Baird cut their target price on Mersana Therapeutics from $4.00 to $3.00 and set a “neutral” rating on the stock in a research report on Wednesday, August 14th. Citigroup cut their price target on Mersana Therapeutics from $6.00 to $5.00 and set a “buy” rating on the stock in a report on Tuesday, August 27th. Finally, Lifesci Capital upgraded shares of Mersana Therapeutics to a “strong-buy” rating in a research note on Monday, July 29th. Two equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Mersana Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $6.00.
Check Out Our Latest Analysis on MRSN
Mersana Therapeutics Company Profile
Mersana Therapeutics, Inc, a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has research and development collaborations with Janssen Biotech, Inc, Ares Trading SA, Merck KGaA, and Asana BioSciences, LLC for the development of ADC product candidates.
Featured Articles
- Five stocks we like better than Mersana Therapeutics
- What is a Dividend Harvesting Strategy and How Can Investors Profit from it?
- 3 Momentum Trades for October With Ample Upside Ahead
- What Does a Gap Up Mean in Stocks? How to Play the Gap
- Roblox Dips on Short Report—Here’s Why It Could Bounce Back Fast
- Buy P&G Now, Before It Sets A New All-Time High
- 2 Reasons to Jump on Apple Stock Now and 1 Reason to Think Twice
Receive News & Ratings for Mersana Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mersana Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.